Literature DB >> 15730996

Erythropoietin-producing renal cell carcinoma arising from autosomal dominant polycystic kidney disease.

Y Hama1, T Kaji, K Ito, M Hayakawa, M Tobe, S Kosuda.   

Abstract

Erythropoietin (EPO)-producing renal cell carcinomas (RCC) in patients with chronic renal failure secondary to autosomal dominant polycystic kidney disease (ADPKD) has not previously been reported. We report a case of EPO-producing RCC associated with ADPKD in a 66-year-old woman, and discuss the clinical and radiological findings.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15730996     DOI： 10.1259/bjr/28214940

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


  4 in total

1.  Identification of the primary tumour with the help of diffusion-weighted MRI in a patient with autosomal dominant polycystic kidney disease and metastatic renal cell carcinoma.

Authors:  M Zeile; D Andreou; A Poellinger; P U Tunn; O Dudeck
Journal:  Br J Radiol       Date:  2011-07       Impact factor: 3.039

2.  JAK2 Unmutated Polycythaemia-Real-World Data of 10 Years from a Tertiary Reference Hospital.

Authors:  Katarzyna Aleksandra Jalowiec; Kristina Vrotniakaite-Bajerciene; Jakub Jalowiec; Noel Frey; Annina Capraru; Tatiana Wojtovicova; Raphael Joncourt; Anne Angelillo-Scherrer; Andre Tichelli; Naomi Azur Porret; Alicia Rovó
Journal:  J Clin Med       Date:  2022-06-13       Impact factor: 4.964

3.  Multifocal renal cell carcinoma of different histological subtypes in autosomal dominant polycystic kidney disease.

Authors:  Ki Yong Na; Hyun-Soo Kim; Yong-Koo Park; Sung-Goo Chang; Youn Wha Kim
Journal:  Korean J Pathol       Date:  2012-08-23

4.  Erythropoietin production in renal cell carcinoma and renal cysts in autosomal dominant polycystic kidney disease in a chronic dialysis patient with polycythemia: A case report.

Authors:  Keiichi Ito; Takako Asano; Susumu Tominaga; Hidehiko Yoshii; Harutake Sawazaki; Tomohiko Asano
Journal:  Oncol Lett       Date:  2014-08-21       Impact factor: 2.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.